

Endo International plc Corporate Fact Sheet

Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company.

Endo's strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success.

Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide.* For more information about Endo International and our operating companies, please visit www.endo.com.

*As of 03/30/2018

Our Operating Companies

Endo International plc



Operating Companies



Develops and markets high-value, quality branded pharmaceutical products to patients in need.




Develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life.



Providing innovative pharmaceutical products for the Canadian market.

Our Global Presence



Our Vision for the Future

Our organization will continue to remain steadfast in our commitment to deliver pharmaceutical products of uncompromising quality and value with the highest levels of service. We will focus on smart product selection, operational execution and continuous improvement, consistently improving how we work, and how we develop and deliver the products we make. We will work as a unified company, creating a cohesive and efficient structure that supports both our Generics and Branded businesses. We will build out our portfolio and capabilities with a focus on core assets and businesses that are critical to our success.


At Endo, our high-performance organization has fostered an entrepreneurial culture that emphasizes integrity and compliance. Performance Driven, Integrity, Quality & Continuous Improvement, Customer Focus and Collaboration are the Core Values that drive and inspire our employees and enable us to deliver superior service and products, as well as make a positive impact on our patients and customers.

Our Management Team

Paul V. Campanelli*	<i>President, Chief Executive Officer and Director</i>
Joseph A. Barbarite	<i>Executive Vice President, Global Quality and Compliance</i>
Patrick Barry*	<i>Executive Vice President and Chief Commercial Officer, U.S. Branded Business</i>
Mark Bradley	<i>Senior Vice President, Corporate Development and Treasurer</i>
Blaise Coleman*	<i>Executive Vice President and Chief Financial Officer</i>
Terrance J. Coughlin*	<i>Executive Vice President and Chief Operating Officer</i>
Larry Cunningham	<i>Executive Vice President, Human Resources</i>
Rahul Garella	<i>Senior Vice President, Head of International Pharmaceuticals</i>
Matthew Maletta*	<i>Executive Vice President, Chief Legal Officer</i>
Carrie A. Nichol*	<i>Vice President, Controller and Chief Accounting Officer</i>
Tony Pera*	<i>President, Par Pharmaceutical</i>
Brandon Rockwell	<i>Senior Vice President, Business Development</i>
Susan Williamson	<i>Senior Vice President and Chief Compliance Officer</i>

*Section 16(b) Executive Officers

Our History



Our Corporate Information

Endo Global Headquarters

First Floor, Minerva House
Simmons Court Road
Ballsbridge
Dublin 4
Ireland
+353 1 268 2000

Endo U.S. Headquarters

1400 Atwater Drive
Malvern, PA 19355
484-216-0000
(800) 462-ENDO (3636)

NASDAQ Ticker Symbol: ENDP

Revised: June 2018

Media

Heather Zoumas-Lubeski
Executive Director, Corporate Affairs
484-216-6829
zoumaslubeski.heather@endo.com

Investors

Nina Goworek
Senior Director, Investor Relations
484-216-6657
goworek.nina@endo.com



© 2018 Endo Pharmaceuticals Inc. www.endo.com